reported the lack of effect of spiramycin on cyclosporin pharmacokinetics. This study confirms our previously published data showing that spiramycin does not increase plasma cyclosporin concentrations in renal transplant patients (Kessler et al., 1988) . Our study included seven cadaveric renal transplant patients (three men and four women), aged 24 to 59 years. The mean duration of graft was 8 months (range: 1 to 14 months). All patients were treated with cyclosporin (mean ± s.d.: 3.6 ± 1.3 mg kg-' day) in association with prednisone (13.7 ± 9.4 mg day). Renal graft function was stable in all patients and their serum creatinine level averaged 181.6 ± 43.3 ,umol 1-I prior to the administration of spiramycin. Plasma cyclosporin concentrations were measured using the polyclonal Sandoz RIA kit. The mean plasma cyclosporin trough concentration was 57.6 ± 24.7 ng ml-1. Spiramycin was administered because of upper respiratory tract infections (four patients), dental care (two patients) and toxoplasmosis (one patient) for a mean duration of 31 days (range 6 to 135 days). During the 30 first days of coadministration of spiramycin and cyclosporin no significant modification (paired t-test and T Wilcoxon test) of plasma cyclosporin concentrations or serum creatinine was detected (Table 1) .
Macrolide antibiotics are prescribed for many types of infections, particularly for infections of the upper and lower respiratory tract. The potential for interactions is not the same for all of these antibiotics. Troleandomycin appears to be the most potent inhibitor of drug metabolism, erythromycin has a much weaker action (Kessler et al., 1986) , josamycin has seldom been involved (Kreft-Jais et al., 1987) and spiramycin and midecamycin have not been shown to inhibit.
We confirm that spiramycin does not modify the metabolism of cyclosporin. Therefore, its use in transplant patients treated with cyclosporin may be recommended. 
